HealthTechX returns to London on 23 February 2023 at the Hurlingham Club — exploring the digitisation of pharma
Exploring the digitisation of pharma on 23 February 2023 at the Hurlingham Club in London
Connecting founders, investors, healthcare providers, operators, opinion leaders and policy makers of the technology-enabled pharmaceutical services sector — the HealthTechX Summit is a one day event exploring how technology is creating change across the pharma industry.
Through insightful thought-leadership content, exclusive networking opportunities, an extended sit-down lunch and closing cocktail reception, HealthTechX provides a unique environment for creating invaluable connections and sharing knowledge.
About HealthTechX
Launched as a one-off event in 2017, the team behind the highly successful EdTechX event series are reigniting the HealthTechX brand with the support of our founding partner IBIS Capital, the specialist investment and corporate finance advisory group. With the recent announcement of IBIS’ advisory services enabling Docquity’s $44m Series C investment round, the firm continues to demonstrate its leading position in the HealthTech sector and looks forward to powering next year’s HealthTechX Summit. Explore the event website: https://healthtechx.com/
Register before the end of October to save £240 on HealthTechX tickets. Further discounts are available for startups, non-profits and government officials. Register here.
Insights and reports
In addition to our thought leadership summits, we share the latest industry insights, trends and ideas through a series of editorials, articles and reports — keeping the global health technology community up-to-date on the positive impact that technology is having across the sector.
In November 2022, the HealthTechX Global Report: Digitisation of Pharma will be released, providing an assessment of the technology-enabled pharmaceuticals sector, including:
- Key sector trends
- Public market analysis
- M&A and fundraising activity
- Company landscape and business model analysis
- Insights from industry leaders
- Investment outlook.
